Overview

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Onyx Therapeutics, Inc.